Marcus Ruscetti to Cell Line, Tumor
This is a "connection" page, showing publications Marcus Ruscetti has written about Cell Line, Tumor.
Connection Strength
1.253
-
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Nov 14; 85(22):4359-4379.
Score: 0.171
-
Chowdhury SR, Parikh CN, Kaur AN, DeMarco KD, Giwa HK, Mishra AK, Murphy KC, Zhou L, Ma B, Ye T, Li J, Liu H, Bai S, Johnson C, Simin K, Pitarresi JR, Zhu LJ, Watson EV, Kelliher MA, Green MR, Fitzgerald KA, Ruscetti M. PPT1 is a negative regulator of STING signaling in cancer cells and its inhibition reactivates immune surveillance in cold tumors. Proc Natl Acad Sci U S A. 2025 Sep 30; 122(39):e2514948122.
Score: 0.169
-
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 08 28; 16(762):eadj9366.
Score: 0.157
-
Chowdhury SR, Murphy KC, Parikh CN, DeMarco KD, Zhou L, Ruscetti M. Measuring the impact of therapy-induced senescence on NK cell phenotypes in cancer. Methods Cell Biol. 2024; 190:171-201.
Score: 0.157
-
Chibaya L, Murphy KC, DeMarco KD, Gopalan S, Liu H, Parikh CN, Lopez-Diaz Y, Faulkner M, Li J, Morris JP, Ho YJ, Chana SK, Simon J, Luan W, Kulick A, de Stanchina E, Simin K, Zhu LJ, Fazzio TG, Lowe SW, Ruscetti M. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat Cancer. 2023 06; 4(6):872-892.
Score: 0.143
-
Ruscetti M, Morris JP, Mezzadra R, Russell J, Leibold J, Romesser PB, Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe SW. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 2020 04 16; 181(2):424-441.e21.
Score: 0.116
-
Ruscetti M, Dadashian EL, Guo W, Quach B, Mulholland DJ, Park JW, Tran LM, Kobayashi N, Bianchi-Frias D, Xing Y, Nelson PS, Wu H. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene. 2016 07 21; 35(29):3781-95.
Score: 0.086
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
Score: 0.045
-
Chava S, Bugide S, Malvi P, DeMarco KD, Ma B, Parikh CN, Ruscetti M, Zajac A, Cai G, Gupta R, Wajapeyee N. Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-?1 suppression. EMBO Mol Med. 2026 01; 18(1):232-274.
Score: 0.043
-
Sun W, Weng W, Shi J, Ma B, D DeMarco K, Gui F, Jin R, Ruscetti M, Jia L, Hu W, Shi Y, Meng X. SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations. Bioconjug Chem. 2025 10 15; 36(10):2158-2171.
Score: 0.042
-
Weissenrieder JS, Peura J, Paudel U, Bhalerao N, Weinmann N, Johnson C, Wengyn M, Drager R, Furth EE, Simin K, Ruscetti M, Stanger BZ, Rustgi AK, Pitarresi JR, Foskett JK. Mitochondrial Ca2+ controls pancreatic cancer growth and metastasis by regulating epithelial cell plasticity. Cell Rep. 2025 May 27; 44(5):115627.
Score: 0.041
-
Perego M, Yeon M, Agarwal E, Milcarek AT, Bertolini I, Camisaschi C, Ghosh JC, Tang HY, Grandvaux N, Ruscetti M, Kossenkov AV, Preston-Alp S, Tempera I, Auslander N, Altieri DC. Parkin activates innate immunity and promotes antitumor immune responses. J Clin Invest. 2024 08 30; 134(22).
Score: 0.039
-
Zou Y, Qi Z, Guo W, Zhang L, Ruscetti M, Shenoy T, Liu N, Wu H. Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Ka/?/d Inhibitor BAY1082439. Mol Cancer Ther. 2018 10; 17(10):2091-2099.
Score: 0.026
-
Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-Frias D, Sybert E, Priceman SJ, Wu L, Nelson PS, Smale ST, Wu H. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol. 2014 Jun; 34(11):2017-28.
Score: 0.019